文章：

肾细胞癌的当前治疗策略：聚焦细胞免疫疗法

Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy

原文发布日期：19 March 2024

DOI: 10.3390/cancers16061209

类型: Article

开放获取: 是

英文摘要：

Renal cell carcinoma (RCC) affects over 400,000 patients globally each year, and 30% of patients present with metastatic disease. Current standard of care therapy for metastatic RCC involve TKIs and ICIs, including combinatorial strategies, but this offers only modest clinical benefit. Novel treatment approaches are warranted, and cell-based immunotherapies for RCC hold significant promise. These are currently being tested in the pre-clinical setting and in early phase clinical trials. Here, we review the landscape of cellular immunotherapy for RCC in the context of currently available therapies, with a particular focus on defining the current best antigenic targets, the range of cell therapy products being explored in RCC, and how advanced engineering solutions may further enhance these therapies in the RCC space.

摘要翻译： 

肾细胞癌每年影响全球超过40万患者，其中30%的患者确诊时已发生转移。目前转移性肾细胞癌的标准治疗方案涉及酪氨酸激酶抑制剂和免疫检查点抑制剂，包括联合治疗策略，但仅能提供有限的临床获益。因此需要开发新型治疗方法，而基于细胞的肾细胞癌免疫疗法展现出巨大潜力。这类疗法目前正处于临床前研究及早期临床试验阶段。本文在现有治疗方案的背景下，系统综述肾细胞癌细胞免疫治疗的发展现状，重点探讨当前最佳抗原靶点的界定、肾细胞癌领域探索中的各类细胞治疗产品，以及先进工程技术如何进一步提升肾细胞癌治疗水平。

原文链接：

Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy